These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 31134509)

  • 1. Successful treatment of acute myeloid leukemia co-expressing NUP98/NSD1 and FLT3/ITD with preemptive donor lymphocyte infusions.
    Mitani Y; Hiwatari M; Seki M; Hangai M; Takita J
    Int J Hematol; 2019 Oct; 110(4):512-516. PubMed ID: 31134509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NUP98::NSD1 and FLT3/ITD co-expression is an independent predictor of poor prognosis in pediatric AML patients.
    Wang JW; Yu-Li ; Yang XG; Xu LH
    BMC Pediatr; 2024 Aug; 24(1):547. PubMed ID: 39182032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
    Shimada A; Iijima-Yamashita Y; Tawa A; Tomizawa D; Yamada M; Norio S; Watanabe T; Taga T; Iwamoto S; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Saito AM; Kiyokawa N; Horibe K; Hara Y; Oki K; Hayashi Y; Tanaka S; Adachi S
    Int J Hematol; 2018 May; 107(5):586-595. PubMed ID: 29330746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3-ITD positive AML.
    Miyajima T; Onozawa M; Yoshida S; Miyashita N; Kimura H; Takahashi S; Yokoyama S; Matsukawa T; Goto H; Sugita J; Fujisawa S; Hidaka D; Ogasawara R; Mori A; Matsuoka S; Shigematsu A; Wakasa K; Kasahara I; Saga T; Hashiguchi J; Takeda Y; Ibata M; Yutaka T; Fujimoto K; Kondo T; Teshima T
    Eur J Haematol; 2023 Oct; 111(4):620-627. PubMed ID: 37465857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report.
    Ostronoff F; Othus M; Gerbing RB; Loken MR; Raimondi SC; Hirsch BA; Lange BJ; Petersdorf S; Radich J; Appelbaum FR; Gamis AS; Alonzo TA; Meshinchi S
    Blood; 2014 Oct; 124(15):2400-7. PubMed ID: 25145343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of three pediatric AML co-expressing NUP98-NSD1, FLT3-ITD, and WT1.
    Liu L; Nie Q; Xiao Z; Chen X; Yang C; Mao X; Li N; Zhou Y; Guo Q; Tian X
    BMC Pediatr; 2024 Jul; 24(1):483. PubMed ID: 39068406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib and navitoclax act synergistically to target NUP98-NSD1
    Kivioja JL; Thanasopoulou A; Kumar A; Kontro M; Yadav B; Majumder MM; Javarappa KK; Eldfors S; Schwaller J; Porkka K; Heckman CA
    Leukemia; 2019 Jun; 33(6):1360-1372. PubMed ID: 30568173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction.
    Thanasopoulou A; Tzankov A; Schwaller J
    Haematologica; 2014 Sep; 99(9):1465-71. PubMed ID: 24951466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.
    Nasilowska-Adamska B; Czyz A; Markiewicz M; Rzepecki P; Piatkowska-Jakubas B; Paluszewska M; Dzierzak-Mietla M; Solarska I; Borg K; Prochorec-Sobieszek M; Szydlo R; Lewandowski K; Skotnicki A; Jedrzejczak WW; Kyrcz-Krzemien S; Komarnicki M; Warzocha K
    Eur J Haematol; 2016 Mar; 96(3):236-44. PubMed ID: 25912052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive Minimal Residual Disease of FLT3-ITD before Hematopoietic Stem Cell Transplantation Resulted in a Poor Prognosis of an Acute Myeloid Leukemia.
    Iwasaki Y; Nishiuchi R; Aoe M; Takahashi T; Watanabe H; Tokorotani C; Kikkawa K; Shimada A
    Acta Med Okayama; 2017 Feb; 71(1):79-83. PubMed ID: 28238014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor.
    Ando T; Sano H; Yokoo M; Kusaba K; Kidoguchi K; Yamaguchi K; Katsuya H; Yoshihara S; Kubota Y; Kojima K; Kimura S
    Int J Hematol; 2020 Aug; 112(2):249-253. PubMed ID: 32185622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial.
    Shiba N; Ohki K; Kobayashi T; Hara Y; Yamato G; Tanoshima R; Ichikawa H; Tomizawa D; Park MJ; Shimada A; Sotomatsu M; Arakawa H; Horibe K; Adachi S; Taga T; Tawa A; Hayashi Y
    Br J Haematol; 2016 Feb; 172(4):581-91. PubMed ID: 26684393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined treatment with venetoclax, dasatinib, and FLT3 inhibitors for NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia: A pediatric case report.
    Wen X; Wu Y; Huang P; Zheng H
    Pediatr Blood Cancer; 2023 Jul; 70(7):e30308. PubMed ID: 36965174
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical significance of monitoring NUP98::NSD1 fusion genes before and after allogeneic hematopoietic stem cell transplantation].
    Shang YK; Pan XA; Chang YJ; Qin YQ; Wang Y; Yan CH; Sun YQ; Huang XJ; Zhao XS
    Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):1010-1015. PubMed ID: 38503524
    [No Abstract]   [Full Text] [Related]  

  • 15. [Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].
    Gu B; Chen GH; Shen HJ; Ma X; Fu CC; Han Y; Tang XW; Miao M; Qiu HY; Sun AN; Wu DP
    Zhonghua Nei Ke Za Zhi; 2016 Apr; 55(4):293-7. PubMed ID: 27030618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
    Tarlock K; Chang B; Cooper T; Gross T; Gupta S; Neudorf S; Adlard K; Ho PA; McGoldrick S; Watt T; Templeman T; Sisler I; Garee A; Thomson B; Woolfrey A; Estey E; Meshinchi S; Pollard JA
    Pediatr Blood Cancer; 2015 Jun; 62(6):1048-54. PubMed ID: 25662999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation.
    Kida M; Kuroda Y; Kido M; Chishaki R; Kuraoka K; Ito T
    Int J Hematol; 2020 Aug; 112(2):243-248. PubMed ID: 32170661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NUP98-NSD1 fusion in association with FLT3-ITD mutation identifies a prognostically relevant subgroup of pediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR.
    Akiki S; Dyer SA; Grimwade D; Ivey A; Abou-Zeid N; Borrow J; Jeffries S; Caddick J; Newell H; Begum S; Tawana K; Mason J; Velangi M; Griffiths M
    Genes Chromosomes Cancer; 2013 Nov; 52(11):1053-64. PubMed ID: 23999921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric acute myeloid leukemia co-expressing FLT3/ITD and NUP98/NSD1 treated with gilteritinib plus allogenic peripheral blood stem cell transplantation: A case report.
    Abematsu T; Nishikawa T; Shiba N; Iijima-Yamashita Y; Inaba Y; Takahashi Y; Nakagawa S; Kodama Y; Okamoto Y; Kawano Y
    Pediatr Blood Cancer; 2021 Nov; 68(11):e29216. PubMed ID: 34245496
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.